CClinicalTrials.gg
CompletedNCT06118112Updated Apr 13, 2026

Living With Long COVID: LONGCOVID-EXPERIENCE

An observational study in Long COVID and Experience, Life, sponsored by Corporacion Parc Tauli. Completed at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Corporacion Parc Tauli · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
25
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Background: One in ten people infected with COVID-19 presents persistent COVID, which consists of the presence of symptoms three months after the acute manifestations of COVID-19 and their persistence for at least two months, without being explained by an alternative diagnosis. The characteristics and clinical approach to persistent COVID syndrome are fairly well known, but not what the experience of people with persistent COVID is in relation to their daily life, their work life, and their experience with the healthcare received. Objective: to understand the experience of patients with persistent COVID in relation to the disease, the health care received and re-entry into the world of work

Methods: Qualitative, descriptive, phenomenological study, based on individual interviews. The study protocol will be registered in Clinicaltrials.gov. People with persistent COVID treated at the Parc Taulí Hospital will be included. Sampling will be by convenience, purposive and snowball and the sample size will be determined by data saturation. Semi-structured individual or group interviews will be conducted and the data will be analyzed following a reflective thematic analysis (Brawn and Clarke). The preliminary report will be triangulated with some participants and with the results obtained from a scoping review carried out by the research team.

02

Conditions studied

  • Long COVID
  • Experience, Life

Keywords

  • Post-Acute COVID-19 Syndrome
  • patient experience
  • qualitative research
03

In context

Post-Acute COVID-19 Syndrome

520 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 186 are open to participants now.

This study's enrollment of 25 is below the median of 160 across 141 observational studies indexed under Post-Acute COVID-19 Syndrome.

Browse Post-Acute COVID-19 Syndrome studies →

Lead sponsor

Corporacion Parc Tauli is the lead sponsor of 163 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients treated at the Parc Taulí Hospital Universitari, a hospital with a reference population of 400,000 urban people and 4,500 workers.

Inclusion criteria

  • women and men diagnosed with persistent COVID between March '20 to the present according to WHO criteria (persistent symptoms three months after the acute manifestations of COVID-19 and lasting at least two months and cannot be explained by an alternative diagnosis).
  • treated at the Parc Taulí Hospital
  • from 18 to 65 years

Exclusion criteria

Exclusion Criteria:

-people who do not understand or can communicate in Catalan or Spanish.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
25 participants (actual)
Patient registry
No

Groups and cohorts

  • Persons with- long-covid

    Women and men diagnosed with persistent COVID according to WHO (World HEalth Organization) criteria: persistent symptoms three months after the acute manifestations of COVID-19 and lasting at least two months and cannot be explained by an alternative diagnosis.

06

What researchers measure

Primary outcomes

  1. Experience of the disease

    How is living with LongCOVID. Assessed through semi-structured interviews.

    Time frame: Up to three years

  2. Experience with healthcare received

    How is the experience of patients with the healthcare received for their condition. Assessed through semi-structured interviews.

    Time frame: Up to three years

  3. Experience with return to work

    What were the barriers and facilitators for returning to work after the disease. Assessed through semi-structures interviews.

    Time frame: Up to three years

07

Study locations

1 site
  • Corporació Sanitària Parc Taulí
    Sabadell, Barcelona 08208, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06118112
Lead sponsor
Corporacion Parc Tauli
Collaborators
Universitat Autonoma de Barcelona
Responsible party
Anna Selva (Co-principal investigator, Corporacion Parc Tauli) — Principal investigator
First posted
Nov 7, 2023
Start date
Sep 18, 2023
Primary completion
Jun 30, 2024
Completion
Dec 30, 2024
Last update
Apr 13, 2026

Study contacts

Anna Selva, MD, MPH, PhD
principal investigator · Parc Taulí, Hospital Universitari- I3PT
Juan Leiva, PhD
study director · Universitat Autònoma Barcelona
Pilar Peña, MD
principal investigator · Parc Taulí, Hospital Universitari- I3PT

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion